Adding lanreotide to everolimus significantly prolonged progression-free survival compared with everolimus alone in patients ...

Cipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth.

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...